Latest NewsNov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases All Filter By: Year2024202320222021202020192018201720162015Oct 7, 2024HiFiBiO Therapeutics to Showcase DIS® Enabled Translational Insights from Ongoing Phase 1 Clinical Trials for Two Novel Immuno-Oncology Antibodies at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Sep 14, 2024HiFiBiO Therapeutics to Present Phase 1 Clinical Trial Data for Two Novel Immuno-Oncology Antibodies at the 2024 Annual Congress of the European Society for Medical OncologyJun 13, 2024EY Announces Liang Schweizer of HiFiBiO Therapeutics as an Entrepreneur Of The Year® 2024 New England Award WinnerMay 24, 2024HiFiBiO Therapeutics to Present Phase 1 Clinical Trial Data for Two Novel Immuno-Oncology Agonists at the 2024 Annual Meeting of the American Society of Clinical OncologyApr 17, 2024EY Announces Liang Schweizer of HiFiBiO Therapeutics as an Entrepreneur Of The Year® 2024 New England Award Finalist1 2 3 … 17 >
